Economic evaluation of opioid substitution treatment in Greece

dc.contributor.author	Γείτονα, Μαίρη	el
dc.contributor.author	Καραγιάννη, Βιλελμίνη Ι.	el
dc.contributor.author	Πετράτος, Πυθαγόρας	el
dc.date.accessioned	2015-01-09T00:48:54Z
dc.date.issued	2015-01-09
dc.identifier.uri	http://hdl.handle.net/11400/3590
dc.rights	Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/us/	*
dc.source	www.europad.org	en
dc.subject	Economic evaluation
dc.subject	Opioid substitution treatments
dc.subject	methadone
dc.subject	buprenorphine
dc.subject	Οικονομική αξιολόγηση
dc.subject	Εξάρτηση από οπιοειδή
dc.subject	Θεραπείες υποκατάστασης οπιοειδών
dc.subject	Μεθαδόνη
dc.subject	Βουπρενορφίνη
dc.subject	Opioid dependence
dc.title	Economic evaluation of opioid substitution treatment in Greece	en
heal.type	journalArticle
heal.classification	Opioid abuse
heal.classification	Narcotics
heal.classification	Όπιο
heal.classification	Ναρκωτικά
heal.classificationURI	http://id.loc.gov/authorities/subjects/sh85095084
heal.classificationURI	http://lod.nal.usda.gov/34676
heal.classificationURI	N/A-Όπιο
heal.classificationURI	N/A-Ναρκωτικά
heal.keywordURI	http://skos.um.es/unescothes/C01156
heal.keywordURI	http://lod.nal.usda.gov/8456
heal.keywordURI	http://lod.nal.usda.gov/8452
heal.dateAvailable	10000-01-01
heal.language	en
heal.access	forever
heal.recordProvider	Τεχνολογικό Εκπαιδευτικό Ίδρυμα Αθήνας.Σχολή Επαγγελμάτων Υγείας και Πρόνοιας.Τμήμα Δημόσιας Υγείας και Κοινοτικής Υγείας.Κατεύθυνση Δημόσιας Υγείας (Δημόσιας Yγιεινής).	el
heal.publicationDate	2012-09
heal.bibliographicCitation	Geitona, M., Carayanni, V.I. and Petratos, P. (2012) Economic evaluation of opioid substitution treatment in Greece. "Heroin addiction and related clinical problems". 14 (3). pp.77-88.	en
heal.abstract	We performed an economic evaluation of opioid substitution treatment (OST) in Greece using data from the Greek Organization.Against Drugs (OKANA). Cost minimization analysis predicted that buprenorphine monotherapy is more costly than buprenorphine-naloxone therapy. Analyses of cost effectiveness demonstrated that buprenorphine-naloxone was the dominant therapy in terms of mortality avoidance and completion of treatment. Furthermore, compared with methadone, buprenorphine-naloxone reduced the mean cost by 49%; it raised the percentage of participants who completed their treatment ~1.5-fold and reduced the percentage of deaths ~2.5-fold. Budget impact analysis demonstrated that switching to buprenorphine-naloxone treatment would result in significant savings, cut the length of waiting lists, and allow greater access to OST in Greece	en
heal.publisher	Pacini editore and AU CNS	en
heal.journalName	Heroin addiction and related clinical problems	en
heal.journalType	peer-reviewed
heal.fullTextAvailability	true